JCI Insight (Feb 2022)

DDR1 contributes to kidney inflammation and fibrosis by promoting the phosphorylation of BCR and STAT3

  • Corina M. Borza,
  • Gema Bolas,
  • Fabian Bock,
  • Xiuqi Zhang,
  • Favour C. Akabogu,
  • Ming-Zhi Zhang,
  • Mark de Caestecker,
  • Min Yang,
  • Haichun Yang,
  • Ethan Lee,
  • Leslie Gewin,
  • Agnes B. Fogo,
  • W. Hayes McDonald,
  • Roy Zent,
  • Ambra Pozzi

Journal volume & issue
Vol. 7, no. 3

Abstract

Read online

Discoidin domain receptor 1 (DDR1), a receptor tyrosine kinase activated by collagen, contributes to chronic kidney disease. However, its role in acute kidney injury and subsequent development of kidney fibrosis is not clear. Thus, we performed a model of severe ischemia/reperfusion-induced acute kidney injury that progressed to kidney fibrosis in WT and Ddr1-null mice. We showed that Ddr1-null mice had reduced acute tubular injury, inflammation, and tubulointerstitial fibrosis with overall decreased renal monocyte chemoattractant protein (MCP-1) levels and STAT3 activation. We identified breakpoint cluster region (BCR) protein as a phosphorylated target of DDR1 that controls MCP-1 production in renal proximal tubule epithelial cells. DDR1-induced BCR phosphorylation or BCR downregulation increased MCP-1 secretion, suggesting that BCR negatively regulates the levels of MCP-1. Mechanistically, phosphorylation or downregulation of BCR increased β-catenin activity and in turn MCP-1 production. Finally, we showed that DDR1-mediated STAT3 activation was required to stimulate the secretion of TGF-β. Thus, DDR1 contributes to acute and chronic kidney injury by regulating BCR and STAT3 phosphorylation and in turn the production of MCP-1 and TGF-β. These findings identify DDR1 an attractive therapeutic target for ameliorating both proinflammatory and profibrotic signaling in kidney disease.

Keywords